Compare JPMorgan Chase & Co (JPM) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

JPMorgan Chase (JPM) trades at $343.94, up 0.83% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to $194.8B projected for 2026. The stock shows robust fundamentals with a P/E of 14.52 and net income margin of 33.4%, though cash flow trends indicate significant investing outflows.

Outlook remains positive with a consensus price target of $372.73, implying ~8.4% upside. Risks include geopolitical tensions affecting oil markets and cybersecurity threats highlighted in recent news. Institutional ownership is stable, supporting a moderate buy rating amid economic uncertainties discussed by CEO Jamie Dimon.

DENTSPLY SIRONA (XRAY) trades at $13.57, down 3.48% with bearish technical indicators despite a bullish moving average signal. The company shows persistent challenges with negative net income margins (-17.06%) and declining revenue trends from $3.9B in 2022 to $3.7B in 2025. Recent Q1 2026 earnings missed estimates ($0.27 vs. $0.28 expected), continuing a pattern of underperformance. Analyst sentiment remains cautious with a 'Hold' consensus rating and $13.33 price target, slightly below current levels.

The stock faces significant fundamental headwinds including consecutive earnings misses, declining profitability, and rising debt-to-asset ratio (42.88% in 2025). While technical indicators show some bullish momentum, the weak financial performance and negative investor sentiment suggest limited near-term upside potential. The appointment of a new CFO and distribution expansions provide some operational optimism, but execution risks remain elevated.